{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T16:46:27Z","timestamp":1795020387493,"version":"4.10.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc. Diabetol. \u2013 Endocrinol. Rep."],"DOI":"10.1186\/s40842-025-00258-0","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T23:01:29Z","timestamp":1768863689000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cardiac autonomic neuropathy in patients with SGA-treated schizophrenia: a randomized controlled trial of 30\u2009weeks\u2019 treatment with semaglutide"],"prefix":"10.1186","volume":"12","author":[{"given":"Ashok Ainkaran","family":"Ganeshalingam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolai Gundtoft","family":"Uhrenholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidse","family":"Arnfred","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"G\u00e6de","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas Kristian","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Bilenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Frystyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"258_CR1","doi-asserted-by":"publisher","unstructured":"Nordentoft M, Wahlbeck K, H\u00e4llgren J, et al. Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS One. 2013;8. https:\/\/doi.org\/10.1371\/journal.pone.0055176.","DOI":"10.1371\/journal.pone.0055176"},{"key":"258_CR2","doi-asserted-by":"publisher","unstructured":"Larsen JR, Svensson CK, Vedtofte L, et al. High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine. CNS Spectr. Published Online First: 2019. https:\/\/doi.org\/10.1017\/S1092852918001311.","DOI":"10.1017\/S1092852918001311"},{"key":"258_CR3","first-page":"1","volume":"41","author":"ADA","year":"2023","unstructured":"ADA. Standards of care in diabetes-2023 abridged for primary care providers American diabetes association. Am Diabetes Assoc. 2023;41:1\u201328.","journal-title":"Am Diabetes Assoc"},{"key":"258_CR4","doi-asserted-by":"publisher","unstructured":"Pillinger T, Beck K, Gobjila C, et al. Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis. JAMA Psychiarty. 2017;74. https:\/\/doi.org\/10.1001\/jamapsychiatry.2016.3803.","DOI":"10.1001\/jamapsychiatry.2016.3803"},{"key":"258_CR5","doi-asserted-by":"publisher","first-page":"483","DOI":"10.4088\/JCP.v62n0614","volume":"62","author":"JL Elmslie","year":"2001","unstructured":"Elmslie JL, Mann JI, Silverstone JT, et al. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry. 2001;62:483\u201386.","journal-title":"J Clin Psychiatry"},{"key":"258_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/j.2051-5545.2011.tb00036.x","author":"M De Hert","year":"2011","unstructured":"De Hert M, Cohen D, Bobes J, et al. Physical illness in patients with severe mental disorders. ii. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry. 2011, 10. https:\/\/doi.org\/10.1002\/j.2051-5545.2011.tb00036.x.","journal-title":"World Psychiatry"},{"key":"258_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","volume":"10","author":"DE Hert M","year":"2011","unstructured":"Hert M DE, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10:52\u201377.","journal-title":"World Psychiatry"},{"key":"258_CR8","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S2215-0366(15)00115-7","volume":"2","author":"DC Henderson","year":"2015","unstructured":"Henderson DC, Vincenzi B, V AN, et al. Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry. 2015;2:452\u201364.","journal-title":"Lancet Psychiatry"},{"key":"258_CR9","doi-asserted-by":"publisher","first-page":"3B","DOI":"10.1016\/j.amjcard.2011.03.013","volume":"108","author":"RA DeFronzo","year":"2011","unstructured":"DeFronzo RA, Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. The Am J Cardiol. 2011;108:3B\u201324B.","journal-title":"The Am J Cardiol"},{"key":"258_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-244X-7-28","volume":"7","author":"P Mackin","year":"2007","unstructured":"Mackin P, Bishop DR, Watkinson HMO. A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients. BMC Psychiatry. 2007;7:1\u20136.","journal-title":"BMC Psychiatry"},{"key":"258_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ijcard.2007.10.042","volume":"127","author":"G Marazzi","year":"2008","unstructured":"Marazzi G, Volterrani M, Rosano GMC. Metabolic agents in the management of diabetic coronary patients: a new era. Int J Cardiol. 2008;127:124\u201325.","journal-title":"Int J Cardiol"},{"key":"258_CR12","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951\u201362.","journal-title":"Lancet"},{"key":"258_CR13","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.2337\/dc10-1303","volume":"33","author":"S Tesfaye","year":"2010","unstructured":"Tesfaye S, Boulton AJM, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285\u201393.","journal-title":"Diabetes Care"},{"key":"258_CR14","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/dmrr.1239","volume":"27","author":"V Spallone","year":"2011","unstructured":"Spallone V, Ziegler D, Freeman R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011;27:639\u201353.","journal-title":"Diabetes Metab Res Rev"},{"key":"258_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4239\/wjd.v5.i1.17","volume":"5","author":"G Dimitropoulos","year":"2014","unstructured":"Dimitropoulos G. Cardiac autonomic neuropathy in patients with diabetes mellitus. World J Diabetes. 2014;5:17.","journal-title":"World J Diabetes"},{"key":"258_CR16","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/08039488.2021.1902566","volume":"75","author":"M Omar","year":"2021","unstructured":"Omar M, Wieben ES, Polcwiartek C, et al. Cardiovascular autonomic neuropathy in patients with schizophrenia. Nord J Psychiatry. 2021;75:547\u201352.","journal-title":"Nord J Psychiatry"},{"key":"258_CR17","doi-asserted-by":"publisher","first-page":"100252","DOI":"10.1016\/j.ahjo.2023.100252","volume":"26","author":"L Blok-Husum","year":"2023","unstructured":"Blok-Husum L, Brcelic MAR, Bassi HKFK, et al. Cardiovascular autonomic reflex tests using a handheld device in the diagnosis of cardiovascular autonomic neuropathy in patients with schizophrenia. Am Hear J Plus Cardiol Res Pract. 2023;26:100252.","journal-title":"Am Hear J Plus Cardiol Res Pract"},{"key":"258_CR18","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.2337\/dc18-1411","volume":"41","author":"ST Andersen","year":"2018","unstructured":"Andersen ST, Witte DR, Fleischer J, et al. Risk factors for the presence and progression of cardiovascular autonomic neuropathy in type 2 diabetes: addition-denmark. Diabetes Care. 2018;41:2586\u201394.","journal-title":"Diabetes Care"},{"key":"258_CR19","doi-asserted-by":"publisher","unstructured":"Serhiyenko VA, Serhiyenko AA. Cardiac autonomic neuropathy: risk factors, diagnosis and treatment. World J Diabetes. Published Online First: 2018. https:\/\/doi.org\/10.4239\/wjd.v9.i1.1.","DOI":"10.4239\/wjd.v9.i1.1"},{"key":"258_CR20","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1210\/jc.2006-2175","volume":"92","author":"J-S Wu","year":"2007","unstructured":"Wu J-S, Yang Y-C, Lin T-S, et al. Epidemiological evidence of altered cardiac autonomic function in subjects with impaired glucose tolerance but not isolated impaired fasting glucose. J Clin Endocrinol Metab. 2007;92:3885\u201389.","journal-title":"J Clin Endocrinol Metab"},{"key":"258_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jdi.12042","volume":"4","author":"AI Vinik","year":"2013","unstructured":"Vinik AI, Erbas T, Casellini CM. Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. J Diabetes Investig. 2013;4:4\u201318.","journal-title":"J Diabetes Investig"},{"key":"258_CR22","doi-asserted-by":"publisher","first-page":"304","DOI":"10.4088\/JCP.08m04718yel","volume":"71","author":"DL Kelly","year":"2010","unstructured":"Kelly DL, McMahon RP, Liu F, et al. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry. 2010;71:304\u201311.","journal-title":"J Clin Psychiatry"},{"key":"258_CR23","doi-asserted-by":"publisher","unstructured":"Vistisen D, Witte DR, Brunner EJ, et al. Risk of cardiovascular disease and death in individuals with prediabetes defined by different criteria: the whitehall ii study. Diabetes Care. Published Online First: 2018. https:\/\/doi.org\/10.2337\/dc17-2530.","DOI":"10.2337\/dc17-2530"},{"key":"258_CR24","doi-asserted-by":"publisher","unstructured":"Cooper SJ, Reynolds GP, Barnes TRE, et al. Bap guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol. Published Online First: 2016. https:\/\/doi.org\/10.1177\/0269881116645254.","DOI":"10.1177\/0269881116645254"},{"key":"258_CR25","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","volume":"74","author":"JR Larsen","year":"2017","unstructured":"Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiarty. 2017;74:719\u201328.","journal-title":"JAMA Psychiarty"},{"key":"258_CR26","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/dom.14334","volume":"23","author":"CA Whicher","year":"2021","unstructured":"Whicher CA, Price HC, Phiri P, et al. The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: results of a pilot randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2021;23:1262\u201371.","journal-title":"Diabetes Obes Metab"},{"key":"258_CR27","doi-asserted-by":"crossref","unstructured":"Siskind D, Baker A, Arnautovska U, et al. Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia. Lancet Psychiatry. 2025;12:493\u2013503.","DOI":"10.1016\/S2215-0366(25)00129-4"},{"key":"258_CR28","doi-asserted-by":"publisher","unstructured":"Ganeshalingam AA, Uhrenholt N, Arnfred S, et al. Semaglutide treatment of antipsychotic-treated patients with schizophrenia, prediabetes, and obesity: the histori randomized clinical trial. JAMA Psychiarty. Published Online First: 3 September 2025. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.2332.","DOI":"10.1001\/jamapsychiatry.2025.2332"},{"key":"258_CR29","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221\u201332.","journal-title":"N Engl J Med"},{"key":"258_CR30","doi-asserted-by":"publisher","first-page":"e077173","DOI":"10.1136\/bmjopen-2023-077173","volume":"14","author":"AA Ganeshalingam","year":"2024","unstructured":"Ganeshalingam AA, Uhrenholt NG, Arnfred S, et al. Home-based intervention with semaglutide treatment of neuroleptic-related prediabetes (histori): protocol describing a prospective, randomised, placebo controlled and double-blinded multicentre trial. BMJ Open. 2024;14:e077173.","journal-title":"BMJ Open"},{"key":"258_CR31","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s00125-020-05316-z","volume":"64","author":"A Eleftheriadou","year":"2021","unstructured":"Eleftheriadou A, Williams S, Nevitt S, et al. The prevalence of cardiac autonomic neuropathy in prediabetes: a systematic review. Diabetologia. 2021;64:288\u2013303.","journal-title":"Diabetologia"},{"key":"258_CR32","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1007\/s00125-015-3534-7","volume":"58","author":"D Ziegler","year":"2015","unstructured":"Ziegler D, Voss A, Rathmann W, et al. Increased prevalence of cardiac autonomic dysfunction at different degrees of glucose intolerance in the general population: the kora S4 survey. Diabetologia. 2015;58:1118\u201328.","journal-title":"Diabetologia"},{"key":"258_CR33","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1152\/japplphysiol.00811.2006","volume":"102","author":"KJ B\u00e4r","year":"2007","unstructured":"B\u00e4r KJ, Boettger MK, Berger S, et al. Decreased baroreflex sensitivity in acute schizophrenia. J Appl Physiol. 2007;102:1051\u201356.","journal-title":"J Appl Physiol"},{"key":"258_CR34","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s10286-003-0131-5","volume":"13","author":"MW Chapleau","year":"2003","unstructured":"Chapleau MW. Determinants of baroreflex sensitivity in health and disease: from correlates to causality. Clin Auton Res. 2003;13:310\u201313.","journal-title":"Clin Auton Res"},{"key":"258_CR35","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.schres.2007.10.005","volume":"98","author":"RM Capasso","year":"2008","unstructured":"Capasso RM, Lineberry TW, Bostwick JM, et al. Mortality in schizophrenia and schizoaffective disorder: an olmsted county, Minnesota cohort: 1950-2005. Schizophr Res. 2008;98:287\u201394.","journal-title":"Schizophr Res"},{"key":"258_CR36","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1192\/bjp.184.47.s64","volume":"47","author":"D Kohen","year":"2004","unstructured":"Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry Suppl. 2004;47:S64\u20136.","journal-title":"Br J Psychiatry Suppl"},{"key":"258_CR37","doi-asserted-by":"crossref","unstructured":"H-A C, C-C C, N-S T, et al. Cardiac autonomic dysregulation in acute schizophrenia. 2013;155\u201364.","DOI":"10.1111\/acn.12014"},{"key":"258_CR38","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1017\/S1461145712001241","volume":"16","author":"WW Fleischhacker","year":"2013","unstructured":"Fleischhacker WW, Siu CO, Bod\u00e9n R, et al. Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European first-episode schizophrenia trial. Int J Neuropsychopharmacol. 2013;16:987\u201395.","journal-title":"Int J Neuropsychopharmacol"},{"key":"258_CR39","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","volume":"156","author":"DB Allison","year":"1999","unstructured":"Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686\u201396.","journal-title":"Am J Psychiatry"},{"key":"258_CR40","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.euroneuro.2020.05.011","volume":"36","author":"E Rose","year":"2020","unstructured":"Rose E, Chen S, Turrion C, et al. Causes of death in clozapine-treated patients in a catchment area: a 10-year retrospective case-control study. Eur Neuropsychopharmacol. 2020;36:160\u201366.","journal-title":"Eur Neuropsychopharmacol"},{"key":"258_CR41","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/clc.4960211005","volume":"21","author":"A Stys","year":"1998","unstructured":"Stys A, Stys T. Current clinical applications of heart rate variability. Clin Cardiol. 1998;21:719\u201324.","journal-title":"Clin Cardiol"},{"key":"258_CR42","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40264-017-0543-0","volume":"40","author":"L Hirsch","year":"2017","unstructured":"Hirsch L, Yang J, Bresee L, et al. Second-generation Antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Saf. 2017;40:771\u201381.","journal-title":"Drug Saf"},{"key":"258_CR43","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1176\/ajp.2006.163.7.1273","volume":"163","author":"JS Lamberti","year":"2006","unstructured":"Lamberti JS, Olson D, Crilly JF, et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry. 2006;163:1273\u201376.","journal-title":"Am J Psychiatry"},{"key":"258_CR44","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s40263-022-00932-2","volume":"36","author":"CU Correll","year":"2022","unstructured":"Correll CU, Agid O, Crespo-Facorro B, et al. A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia. CNS Drugs. 2022;36:659\u201379.","journal-title":"CNS Drugs"},{"key":"258_CR45","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.psychres.2013.07.034","volume":"210","author":"MS Chung","year":"2013","unstructured":"Chung MS, Yang AC, Lin YC, et al. Association of altered cardiac autonomic function with psychopathology and metabolic profiles in schizophrenia. Psychiatry Res. 2013;210:710\u201315.","journal-title":"Psychiatry Res"},{"key":"258_CR46","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"DM Nathan","year":"1993","unstructured":"Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977\u201386.","journal-title":"N Engl J Med"},{"key":"258_CR47","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/S0008-6363(97)00040-0","volume":"34","author":"K Howorka","year":"1997","unstructured":"Howorka K, Pumprla J, Haber P, et al. Effects of physical training on heart rate variability in diabetic patients with various degrees of cardiovascular autonomic neuropathy. Cardiovasc Res. 1997;34:206\u201314.","journal-title":"Cardiovasc Res"},{"key":"258_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2003.143","author":"P Poirier","year":"2003","unstructured":"Poirier P, Hernandez TL, Weil KM, et al. Impact of diet-induced weight loss on the cardiac autonomic nervous system in severe obesity. Obes Res. Published Online First: 2003. https:\/\/doi.org\/10.1038\/oby.2003.143.","journal-title":"Obes Res"}],"container-title":["Cardiovascular Diabetology \u2013 Endocrinology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-025-00258-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40842-025-00258-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-025-00258-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T23:01:30Z","timestamp":1768863690000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40842-025-00258-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["258"],"URL":"https:\/\/doi.org\/10.1186\/s40842-025-00258-0","relation":{},"ISSN":["3059-4057"],"issn-type":[{"value":"3059-4057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"20 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial received approval from the Danish Medicines Agency (2020110216) and The Regional Committees on Health Research Ethics for Southern Denmark (S-20200182). The trial was conducted in strict adherence to the principles outlined in the Helsinki Declaration and Good Clinical Practice guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"Preliminary results from this study were presented at the first ever Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) at the Bella Center in Copenhagen in may 2025.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Meeting presentation"}},{"value":"During the course of preparing this work, the authors used Chat GPT for the purpose of refining language, correcting spelling mistakes and grammar corrections. Following the use of this tool, the authors formally reviewed the content for its accuracy and edited it as necessary. The authors take full responsibility for all the content of this publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of AI"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}